The i-Technology Media!
Register | Log in
   
 
.NET  ·  AJAX  ·  CLOUD  ·  ECLIPSE  ·  FLEX  ·  OPEN WEB  ·  iPHONE  ·  JAVA  ·  LINUX  ·  OPEN SOURCE  ·  ORACLE  ·  PBDJ  ·  SEARCH  ·  SILVERLIGHT  ·  SOA  ·  VIRTUALIZATION  ·  WEB 2.0  ·  WIRELESS  ·  XML
Comments
Plone and Drupal: Different Approaches, Different Results
paul.nowak wrote: Matt, thanks for the comments. I made an error on the version of Plone. It's 2.5 Plone running on Zope 2.9x. In regards to the additional products, we have a skin installed and we have a product that we had custom developed for us that connects to a PostgreSQL database. We've looked at slow PostgreSQL queries causing problems and have not been able to find an issue. We've also tested for the case where the PostgreSQL server is down and have not been able to create an issue. We therefor...
Nov. 4, 2009 04:19 PM EST
Cloud Expo on Google News
Did you read today's front page stories & breaking news?


2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts

2009 East
GOLD SPONSORS:
CA
Get Your Transactions Under Control: SOA Performance Management
Software AG
Performance Driven Adoption: The Secret to Advancing SOA
Intel
The Evolving SOA Appliance: 3 Game-Changing Innovations
SILVER SPONSOR:
Denodo
Data Mashups: Deliver Your Project Faster with Virtualized Data Services Across Internal & External Sources
POWER PANELS:
The Business Value of Service Orientation
Driving Profitability Through User Experience
Click For 2008 West
Event Webcasts
Live Google News by SYS-CON!
Top Three Links You Must Click On


From the Wires
Medistem Laboratories Announces Positive Preclinical Results for MDS-786 Candidate
Non-Toxic Treatment for Lung Cancer Presented at International Stem Cell Meeting

By: Marketwire .
Jun. 29, 2007 11:05 AM

PHOENIX, AZ -- (MARKET WIRE) -- 06/29/07 -- Medistem Laboratories (OTCBB: MDSM) (FRANKFURT: S2U) announced today preclinical proof-of-concept studies demonstrating the positive potential of the company's MDS-786 candidate drug for lung cancer. The findings were presented at the 13th Annual Meeting of the International Society for Cellular Therapy that took place June 24-27, 2007 in Sydney, Australia. The presentation, entitled "Differentiation and Inhibition of Tumor Cells by Cord Blood Stem Cells" reviewed the ability of MDS-786 to induce a process called "differentiation" in which tumor cells are coaxed into transforming into non-tumor cells through the use of a placentally derived product.

Thomas Ichim, Medistem's Chief of Scientific Development and primary author of the paper, stated, "To date, treatment options for patients with lung cancer are primarily limited to highly toxic chemotherapy and radiotherapy approaches, which in many cases are not successful. Through harnessing molecular mechanisms that signal stem cell maturation in normal cells, we are inducing a process that drives malignant cells to convert into non-malignant cells." He continued, "The process of inducing malignant cells to transform into normal cells has been proven clinically as a viable treatment for cancer and is used in the treatment of patients with Acute Promyelocytic Leukemia. By applying such a process to solid tumors, we believe numerous therapeutic applications may exist that lack the toxicity of current approaches."

The National Cancer Institute estimates that over 10 million people are diagnosed with cancer annually. While there are some viable options today for treating some forms of cancer, Medistem is hopeful that MDS-786 can begin to address this dreaded disease in a non-toxic manner by allowing stem cells and the immune system to work in concert with one another to achieve homeostasis.

About Medistem Laboratories, Inc.

Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.

Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.

These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.

Contact:

Medistem Laboratories, Inc.
Chris McGuinn
602-318-3535
http://www.medisteminc.com

Published Jun. 29, 2007
Copyright © 2007 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers

ADS BY GOOGLE

Breaking Java News
Oilsands Quest Provides Reservoir Test Program Update and Announces Participation at Conference
Office Ally Continues to Break Barriers to Electronic Connectivity for Physicians
Vivabox(TM) Unveils Newest Solutions to Holiday Gift Giving
TAM is Awarded the World Travel Awards
Tyler Technologies’ Odyssey® Online Provides an Integrated Case Management Solution to Yoakum and Pecos Counties in Texas
BDNA Webinar Helps Businesses Prepare for and Survive a Software Audit
KACE™ Expands Dell Support With New Appliance
Biosyntrx, Inc. Appoints New CEO
WebMD Announces Drugs.com to Join the WebMD Health Network
Clear Skies Signs $4.8 Million Contract With Microdyne Plastics Inc.

ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS:   |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  Cloud Computing Conference & Expo  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.
 
close this window